Abstract: The present invention provides the new use of composition comprising at least one inhibitor of dipeptidyl peptidase IV (DPP-IV) for increasing migration and homing of haematopoetic progenitor cells in stem cell transplanted recipients, wherein said haematopoetic stem and/or progenitor cells had been treated in vitro with an engraftment enhancing compound, specifically with a prostacyclin analog and a cAMP enhancer before transplantation.

Abstract: The present invention provides a novel method for enhancing engraftment of haematopoetic stem cells by an ex-vivo pretreatment comprising the steps of obtaining a sample containing haematopoetic stem cells and admixing a prostacyclin analog to obtain a mixture, incubating said mixture for a period of time sufficient to stimulate G alphas-signalling in said cells and optionally and isolating said stimulated cells. Further, a composition comprising a prostacyclin analog for use in the treatment of individuals undergoing haematopoetic stem cell transplantation is provided.

Abstract: The present invention provides compositions comprising a prostacyclin or prostacyclin analog, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analog for treating or preventing a condition associated with cystic fibrosis in a subject.

Abstract: The present invention provides an emergency supply valve to support the in situ administration of a drug to a subject in need thereof, comprising an infusion needle connected to a movable piston, wherein said piston is forwarded by infusion solution unable to pass the regular drug line due to kinking or obstruction thereof, a self-sealing membrane that is disrupted by the infusion needle when the piston is in a forward position, a connecting unit that connects the needle to the regular drug conduit when the needle is in a forward position, and a pressure sensitive mechanism that retracts the piston from the forward position when an increased pressure of the drug supply is normalized and its use for the treatment of subjects in need thereof.

Abstract: The present invention provides a composition comprising at least one prostacyclin or prostacyclin analog or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4 inhibitor and optionally a further PDE inhibitor for use in preventing or treating cystic fibrosis by selectively increasing the cAMP levels in bronchoepithelial cells.

Abstract: A method for the preparation of treprostinil and its derivatives is described. In contrast to prior art, this method utilizes an easily scalable enzymatic resolution of a key intermediate for making these compounds. Another significant improvement of the described method over prior methods is the regioselective Claisen rearrangement of a 5-allyloxy-benzaldehyde precursor, which is facilitated by a bromo substituent in 2-position.

Abstract: The present invention provides an emergency supply valve to support the in situ administration of a drug to a subject in need thereof, comprising an infusion needle connected to a movable piston, wherein said piston is forwarded by infusion solution unable to pass the regular drug line due to kinking or obstruction thereof, a self-sealing membrane that is disrupted by the infusion needle when the piston is in a forward position, a connecting unit that connects the needle to the regular drug conduit when the needle is in a forward position, and a pressure sensitive mechanism that retracts the piston from the forward position when an increased pressure of the drug supply is normalized and its use for the treatment of subjects in need thereof.

Abstract: The present invention provides a composition comprising at least one prostacyclin or prostacyclin analogue or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4 inhibitor and optionally a further PDE inhibitor for use in preventing or treating cystic fibrosis by selectively increasing the cAMP levels in bronchoepithelial cells.

Abstract: The present invention provides compositions comprising a prostacyclin or prostacyclin analogue, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analogue for treating or preventing a condition associated with cystic fibrosis in a subject.